vascular
endothelium
consid
organtissu
compris
monolay
endotheli
cell
serv
semiperm
cellular
barrier
separ
inner
space
blood
vessel
surround
tissu
control
exchang
fluid
cell
two
compart
sinc
pulmonari
circul
receiv
entir
cardiac
output
larg
surfac
area
lung
microvasculatur
well
suit
sens
mechan
chemic
cellular
injuri
inhal
circul
substanc
endotheli
barrier
dynam
regul
exposur
variou
stimuli
physiolog
patholog
origin
serv
regul
multipl
key
biolog
process
includ
lung
fluid
balanc
solut
transport
vascular
compart
exampl
increas
vascular
permeabl
necessari
featur
bodi
defens
mechan
provid
injur
tissu
access
leucocyt
result
tissu
edema
due
fluid
extravas
howev
condit
intens
lung
inflamm
observ
acut
lung
injuri
sever
form
acut
respiratori
distress
syndrom
larg
surfac
area
becom
liabil
provid
opportun
profound
vascular
permeabl
result
massiv
fluid
accumul
alveolar
space
progress
lead
pulmonari
failur
alter
vascular
permeabl
occur
acut
inflammatori
lung
disord
primarili
caus
sepsi
pneumonia
trauma
result
high
rate
patient
morbid
mortal
attract
target
therapeut
intervent
subacut
lung
inflammatori
disord
ischemiareperfus
injuri
radiat
lung
injuri
asthma
thu
understand
mechan
endotheli
barrier
dysfunct
vital
manag
treatment
key
enigmat
pulmonari
disord
vascular
endothelium
consid
organ
tissu
compris
monolay
endotheli
cell
ec
serv
semiperm
cellular
barrier
separ
inner
space
blood
vessel
surround
tissu
control
exchang
fluid
cell
two
compart
sinc
pulmonari
circul
receiv
entir
cardiac
output
larg
surfac
area
lung
microvasculatur
well
suit
sens
mechan
chemic
cellular
injuri
inhal
circul
substanc
endotheli
barrier
dynam
regul
exposur
variou
stimuli
physiolog
patholog
origin
serv
regul
multipl
key
biolog
process
includ
lung
fluid
balanc
solut
transport
vascular
compart
exampl
increas
vascular
permeabl
necessari
featur
bodi
defens
mechan
provid
injur
tissu
access
leucocyt
result
tissu
edema
due
fluid
extravas
howev
condit
intens
lung
inflamm
observ
acut
lung
injuri
ali
sever
form
acut
respiratori
distress
syndrom
ard
larg
surfac
area
becom
liabil
provid
opportun
profound
vascular
permeabl
result
massiv
fluid
accumul
alveolar
space
progress
lead
pulmonari
failur
alter
vascular
permeabl
occur
acut
inflammatori
lung
disord
primarili
caus
sepsi
pneumonia
trauma
result
high
rate
patient
morbid
mortal
attract
target
therapeut
intervent
subacut
lung
inflammatori
disord
ischemiareperfus
injuri
radiat
lung
injuri
asthma
thu
understand
mechan
endotheli
barrier
dysfunct
vital
manag
treatment
key
enigmat
pulmonari
disord
key
concept
dynam
regul
lung
ec
barrier
notion
two
gener
pathway
transcellular
paracellular
describ
movement
flow
fluid
macromolecul
leukocyt
interstitium
subsequ
alveolar
air
space
produc
clinic
signific
pulmonari
edema
inflammatori
lung
process
fig
transcellular
pathway
util
tyrosin
kinas
depend
transcytot
albumin
rout
activ
process
albumin
transport
endocyt
vessel
fuse
endothelium
respons
surfac
glycoprotein
receptor
ligat
howev
gener
consensu
primari
mode
fluid
transendotheli
leukocyt
traffick
occur
paracellular
pathway
shown
eleg
electron
microscopi
studi
majno
palad
demonstr
lung
ec
round
paracellular
gap
format
site
activ
inflamm
within
lung
vasculatur
disrupt
integr
ec
monolay
recogn
cardin
featur
inflamm
ischemiareperfus
injuri
angiogenesi
occur
respons
varieti
mechan
stress
factor
inflammatori
mediat
activ
neutrophil
product
reactiv
oxygen
speci
ro
proteas
cation
peptid
dramat
cell
shape
chang
result
paracellular
gap
format
implic
direct
involv
endotheli
structur
compon
compos
cytoskelet
protein
microfila
microtubul
thu
although
perceiv
passiv
cellular
barrier
ec
recogn
highli
dynam
tissu
contribut
multipl
dimens
ec
function
includ
interact
number
barrierregulatori
effector
via
endotheli
cytoskeleton
durat
outcom
inflammatori
diseas
process
depend
upon
balanc
sever
endotheli
injuri
caus
adhes
biophys
forc
mechan
shear
stress
ss
receptor
ligat
specif
inflammatori
mediat
effici
endogen
repair
mechan
restor
vascular
integr
chapter
address
role
cytoskelet
rearrang
mechanist
regul
pulmonari
vascular
barrier
function
permeabl
defin
current
strategi
design
enhanc
integr
lung
vascular
endothelium
identifi
vascular
biomark
potenti
prognost
determin
acut
inflamm
well
accept
dynam
cytoskelet
element
actin
microtubul
intermedi
filament
if
key
element
vascular
barrier
regul
vast
major
studi
contribut
recognit
focus
agonistmedi
signal
actomyosin
cytoskeleton
subsequ
effect
lung
vascular
barrierregulatori
properti
histor
view
separ
distinct
cytoskelet
system
microtubul
actin
filament
known
interact
function
dynam
cellular
process
microtubul
scaffold
complex
central
role
tubulin
dynam
activ
contribut
cytoskelet
rearrang
transduc
compet
barrierregulatori
forc
often
close
collabor
microfila
element
much
less
known
if
enigmat
compon
ec
cytoskeleton
consist
dimer
structur
ahel
protein
combin
form
fibril
protein
express
specif
manner
vimentin
primari
protein
found
ec
role
if
regul
ec
barrier
repres
fertil
area
futur
investig
limit
inform
avail
nevertheless
cytoskelet
constitu
togeth
provid
capac
dynam
regul
cell
shape
consequ
momenttomo
adapt
everchang
vascular
environ
actin
globular
protein
central
locat
atpbind
site
critic
mani
cellular
process
includ
cell
motil
cell
divis
cell
signal
other
shown
ec
permeabl
gactin
revers
assembl
form
polymer
actin
fiber
call
filament
actin
factin
actin
microfila
diamet
confer
strength
structur
element
regul
cell
shape
particularli
accompani
phosphoryl
myosin
dynam
remodel
actin
filament
within
peripher
distribut
cortic
band
essenti
mainten
endotheli
integr
basal
barrier
function
inhibit
actin
polymer
cytochalasin
directli
increas
ec
permeabl
edemagen
agent
initi
dramat
cytoskelet
rearrang
character
loss
peripher
actin
filament
concomit
increas
organ
actin
cabl
span
cell
known
stress
fiber
critic
involv
regul
spatial
local
level
actin
cycl
polymerizationdepolymer
numer
actinbind
protein
serv
crosslink
bundl
protein
polymerizationdepolymer
protein
cappingsev
protein
one
key
actinbind
protein
central
regul
ec
contractil
apparatu
ca
calmodulindepend
nonmuscl
isoform
myosin
light
chain
kinas
nmmlck
phosphoryl
substrat
myosin
light
chain
mlc
nmmlck
central
paracellular
gap
format
increas
permeabl
mani
edemagen
agent
includ
thrombin
vascular
endotheli
growth
factor
vegf
vitro
preclin
model
inflammatori
lung
injuri
studi
nmmlck
knockout
mice
reveal
protect
sepsisinduc
ali
laboratori
shown
nmmlck
knockout
mice
well
mice
treat
inhibitori
peptid
reduc
mlc
kinas
mlck
activ
protect
ventilatorinduc
lung
injuri
vili
addit
shown
genet
variant
singlenucleotid
polymorph
mylk
gene
chromosom
encod
mlck
confer
signific
suscept
sepsi
sepsisand
traumainduc
ali
well
contribut
risk
sever
asthma
african
american
anoth
inflammatori
lung
disord
key
regulatori
featur
nmmlck
posttransl
modif
ptm
increas
level
nmmlck
tyrosin
phosphoryl
catalyz
either
kinas
cabl
kinas
inhibit
tyrosin
phosphatas
vanad
ptm
serv
increas
kinas
activ
modul
ec
barrier
respons
diperoxovanad
potent
tyrosin
phosphatas
inhibitor
also
increas
nmmlck
activ
number
stress
fiber
ec
contract
via
activ
kinas
nmmlck
isoform
bind
cortactin
anoth
actinbind
protein
ec
barrier
regul
local
numer
cortic
structur
within
cell
domain
cortactin
bind
prolinerich
area
nmmlck
interact
enhanc
cortic
actin
format
tensil
strength
central
region
cortactin
bind
crosslink
actin
filament
cterminu
site
kinasemedi
phosphoryl
reduc
crosslink
activ
tyrosin
phosphoryl
cortactin
potenti
stabil
actin
polymer
strengthen
cortactinnmmlck
interact
key
step
sequenc
event
produc
cytoskelet
chang
reassembl
adheren
junction
aj
barrier
restor
lung
inflamm
microtubul
polym
atubulin
btubulin
form
lattic
network
rigid
hollow
rod
span
cell
polar
fashion
nucleu
peripheri
undergo
frequent
assembl
disassembl
import
function
microtubul
includ
intracellular
transport
vesicl
organel
well
signal
transduct
cytoskelet
structur
addit
microtubul
act
concert
actin
cytoskeleton
promot
ec
barrier
integr
microtubul
actin
filament
exhibit
complex
intim
function
interact
dynam
cellular
process
microtubul
disrupt
agent
nocodazol
vinblastin
induc
rapid
assembl
actin
filament
focal
adhes
isometr
cellular
contract
correl
level
mlc
phosphoryl
increas
permeabl
across
ec
monolay
increas
transendotheli
leukocyt
migrat
event
revers
attenu
microtubul
stabil
paclitaxel
mechan
involv
effect
poorli
understood
like
mediat
interact
actin
filament
suggest
signific
microfilamentmicrotubul
cross
talk
disrupt
microtubul
caus
actin
cytoskelet
remodel
cell
contract
decreas
transendotheli
resist
rho
kinas
induc
phosphoryl
mlc
phosphatas
nocadozol
caus
format
stress
fiber
myofila
assembl
accompani
increas
mlc
phosphoryl
remodel
aj
barrier
disrupt
microtubul
stabil
paclitaxel
inhibit
format
stress
fiber
preserv
cellular
shape
intercellular
contact
although
effect
poorli
understood
microfilamentmicrotubul
cross
talk
repres
intrigu
area
ec
barrier
regul
if
third
major
element
involv
ec
cytoskelet
structur
defin
basi
filament
structur
distinguish
microfila
microtubul
despit
greater
divers
highli
conserv
compon
either
actin
microfila
microtubul
protein
share
common
dimer
structur
contain
two
parallel
ahelic
combin
form
polar
fibril
associ
array
ifbind
protein
connect
nuclear
envelop
peripher
cell
junction
cytoskelet
compon
protein
express
highli
cell
specif
manner
vimentin
primari
protein
found
ec
cell
mesenchym
origin
although
data
suggest
potenti
role
if
ec
cytoskelet
structur
barrier
function
effect
like
subtl
subject
compens
biolog
redund
function
if
ec
barrier
regul
much
less
understood
assembl
if
complex
process
like
highli
regul
signal
cascad
associ
cell
motil
vimentin
dynam
structur
undergo
constant
assemblydisassembl
well
anterograd
retrograd
movement
microtubulebas
movement
if
like
critic
assembl
mainten
vimentin
network
physic
dynam
properti
vimentin
network
vascular
ec
like
import
regul
cell
shape
resist
hemodynam
stress
accompani
blood
flow
resist
shear
strain
physiolog
chang
regul
cytoskeleton
ifassoci
protein
serv
intern
scaffold
ec
link
plasma
membran
junction
contact
vimentin
protein
express
higher
macrovascular
ec
line
vessel
subject
highest
hemodynam
strain
aorta
compar
microvascular
ec
line
vessel
less
ss
vimentin
knockout
mice
develop
normal
without
gross
blood
vessel
abnorm
reduc
mesenter
arteri
vessel
dilat
respons
flow
downstream
respons
flow
may
result
intracellular
mechanosign
event
trigger
deform
cytoskeleton
chang
unidirect
laminar
flow
result
rapid
adapt
ec
vimentin
network
direct
displac
within
minut
initi
exposur
note
microfila
microtubul
period
hour
cytoskelet
filament
align
direct
flow
significantli
larger
chang
vimentin
distribut
around
nucleu
compar
displac
occur
cytosol
closer
substrat
observ
spatial
chang
may
mean
distribut
local
shear
forc
transmiss
throughout
cell
therefor
convey
cell
signal
messag
via
mechanosign
pathway
thu
vimentin
if
like
critic
maintain
structur
integr
ec
ss
may
also
conduit
signal
cascad
trigger
mechan
forc
excit
area
futur
examin
dynam
equilibrium
exist
ec
contractil
forc
adhes
proteincytoskeleton
linkag
cellcel
cellmatrix
interact
necessari
proper
barrier
function
major
contributor
intact
cellular
barrier
tight
apposit
individu
ec
neighbor
cell
via
intercellular
junction
collect
contribut
basal
endotheli
barrier
function
two
primari
type
intercellular
contact
ec
aj
tight
junction
tj
link
ec
actin
cytoskeleton
neighbor
cell
provid
mechan
stabil
mediat
signal
transduct
fig
addit
cellcel
junction
stabil
cellmatrix
interact
also
contribut
stabil
barrier
function
specif
compon
focal
adhes
complex
ie
integrinbas
linkag
extracellular
matrix
ecm
endotheli
cytoskeleton
provid
strong
tether
endothelium
vessel
wall
thu
enhanc
barrier
integr
aj
compos
cadherin
bound
togeth
homotypicand
ca
depend
fashion
link
adjac
ec
cadherin
interact
cytoplasm
tail
catenin
famili
intracellular
protein
primarili
bcatenin
turn
provid
anchorag
actin
cytoskeleton
primari
adhes
protein
present
human
endotheli
aj
vascular
endotheli
cadherin
vecadherin
critic
mainten
ec
barrier
integr
demonstr
increas
vascular
permeabl
induc
mice
infus
vecadherin
block
antibodi
similarli
cultur
ec
vecadherin
block
antibodi
enhanc
neutrophil
transendotheli
migrat
produc
reorgan
actin
cytoskeleton
anchorag
vecadherin
actin
cytoskeleton
crucial
maintain
barrier
integr
sinc
cytoplasmicdelet
vecadherin
anchor
actin
cytoskeleton
still
form
cadherincadherin
bind
result
increas
vascular
permeabl
tj
zona
occluden
area
surround
entir
apic
perimet
adjac
cell
form
fusion
outer
layer
plasma
membran
associ
suffici
tight
form
virtual
imperm
barrier
fluid
compos
occludin
claudin
junction
adhes
molecul
coupl
cytoplasm
protein
fig
similar
vecadherin
aj
ec
express
celltypespecif
transmembran
adhes
protein
tj
cytoplasm
compon
tj
link
ec
actin
cytoskeleton
zona
occluden
famili
tj
particularli
abund
promin
brain
microvasculatur
epitheli
cell
strict
control
permeabl
need
contrast
microvascular
bed
ec
particularli
leaki
lung
microvasculatur
less
defin
tj
structur
promin
aj
structur
therefor
aj
tj
histor
consid
primari
target
involv
junction
protein
dissoci
result
increas
paracellular
permeabl
grow
evid
tj
may
play
larger
role
regul
paracellular
permeabl
lung
previous
thought
final
focal
adhes
intim
involv
lung
ec
barrier
regul
via
signal
cytoskeleton
ecm
focal
adhes
attach
ec
underli
ecm
mediat
ecm
protein
ie
collagen
fibronectin
laminin
etc
integrin
cytoplasm
adhes
plaqu
contain
vinculin
talin
paxillin
integrin
coupl
ecm
cytoskeleton
transmit
signal
surround
environ
play
key
role
format
cell
adhes
complex
attach
actin
cytoskeleton
via
cytoskelet
protein
actin
vinculin
talin
aactinin
focal
adhes
primarili
integrin
form
bridg
bidirect
signal
transduct
actin
cytoskeleton
cellmatrix
interfac
disrupt
integrinecm
connect
increas
ec
permeabl
integrin
modul
ec
permeabl
ss
inflammatori
mediat
integrinecm
bind
stimul
tyrosin
phosphoryl
protein
paxillin
cortactin
focal
adhes
kinas
fak
well
calcium
influx
fak
princip
kinas
catalyz
downstream
reaction
integrin
engag
focal
adhes
assembl
fak
activ
regul
tyrosin
phosphoryl
mediat
src
famili
activ
fak
tyrosin
phosphoryl
produc
cell
contract
increas
ec
barrier
permeabl
previous
report
integrin
b
express
dramat
upregul
upon
challeng
barrierprotect
agent
simvastatin
furthermor
upregul
integrin
b
attenu
endotoxinand
ventilatorinduc
express
inflammatori
cytokin
interleukin
il
suggest
novel
mechan
modul
endotheli
barrier
function
via
integrin
b
focal
adhes
signal
inflammatori
mediat
increas
vascular
permeabl
disrupt
endotheli
junction
focal
adhes
complex
well
induc
cellular
contract
open
paracellular
gap
tj
aj
ideal
situat
local
cellcel
junction
logic
key
particip
control
vascular
paracellular
permeabl
monolay
integr
recent
studi
brain
ec
focus
import
claudin
tj
format
mainten
mice
gene
knock
morpholog
alter
vascular
network
tj
structur
pup
die
within
h
birth
owe
sizeselect
loosen
bloodbrain
barrier
molecul
less
kda
appear
moder
redund
among
claudin
isoform
may
allow
format
tj
complet
function
tj
appear
act
concert
form
tightli
organ
strand
network
mutant
maintain
barrier
larger
molecul
suggest
structur
barrier
wherea
crucial
dynam
regul
tj
permeabl
gene
inactiv
occludin
also
effect
vascular
morpholog
barrier
permeabl
suggest
minor
role
tj
function
endothelium
compar
inactiv
gene
mice
caus
defect
develop
vascular
system
embryo
adult
mice
molecul
play
import
role
modul
leukocyt
diapedesi
ec
jamc
howev
uniqu
unlik
junction
protein
increas
endotheli
permeabl
express
ec
surfac
suggest
role
promot
andor
organ
junction
format
activ
mediat
vecadherin
activ
actin
organ
well
kinas
phosphatas
modul
tj
protein
phosphoryl
endotheli
permeabl
mani
studi
tj
use
brain
ec
adhes
molecul
promin
nevertheless
recent
studi
lung
ec
demonstr
despit
less
promin
format
tj
compar
aj
tj
may
play
critic
role
endotheli
barrier
dysfunct
associ
exposur
particul
matter
air
pollut
shown
induc
gradual
prolong
barrier
dysfunct
cultur
lung
endothelium
aj
found
unexpectedli
unalt
tj
specif
degrad
calpaindepend
proteasom
pathway
novel
mechan
lung
endotheli
barrier
regul
contrast
tj
regul
lung
vascular
integr
involv
aj
well
character
although
vecadherin
present
high
concentr
ec
differ
type
vessel
appear
modifi
vecadherin
express
complement
vascular
barrier
function
particular
vessel
four
mode
aj
protein
regul
permeabl
describ
involv
vecadherin
phosphoryl
intern
cleavag
express
simultan
coordin
vecadherin
phosphoryl
intern
appear
crucial
rapid
respons
increas
permeabl
wherea
vecadherin
cleavag
express
progress
alter
edemagen
stimuli
induc
tyrosin
phosphoryl
aj
protein
vecadherin
bcatenin
catenin
parallel
increas
permeabl
tyrosin
kinas
src
implic
phosphoryl
aj
protein
directli
associ
vecadherincatenin
complex
src
gene
inactiv
treatment
inhibitor
block
vegfinduc
vecadherin
phosphoryl
phosphoryl
vecadherin
depend
kinas
activ
well
inhibit
associ
phosphatas
endothelialspecif
phosphatas
veptp
also
associ
vecadherin
inactiv
veptp
gene
lead
phenotyp
compar
vecadherin
null
embryo
suggest
vessel
form
correctli
vecadherin
constantli
phosphoryl
permeabl
may
also
regul
vecadherin
intern
typic
catenin
bind
vecadherin
act
plasma
membran
retent
signal
prevent
vecadherin
intern
howev
upon
challeng
barrierdisrupt
stimuli
activ
src
phosphoryl
guanin
exchang
factor
gef
rac
phosphoryl
vecadherin
induc
barrestin
recruit
promot
clathrindepend
vecadherin
intern
angiopoietin
induc
src
trap
mdia
reduc
activ
aj
thu
reduc
vascular
permeabl
third
pathway
may
induc
vascular
permeabl
vecadherin
cleavag
vecadherin
particularli
suscept
enzymat
proteolysi
specif
elastas
releas
high
amount
leukocyt
promot
vecadherin
cleavag
cell
extravas
vascular
leakag
lastli
permeabl
control
may
also
achiev
vecadherin
gene
express
vecadherin
promot
contain
sever
bind
site
transcript
factor
erg
hypoxiainduc
factor
therefor
interendotheli
junction
key
site
regul
vascular
permeabl
variou
stimuli
target
either
tj
aj
furthermor
variou
combinatori
mode
regul
aj
promot
dissoci
adhes
protein
cellcel
junction
howev
addit
factor
often
accompani
junction
dissoci
disband
cortic
cytoskeleton
increas
cellular
contract
augment
barrier
dysfunct
monolay
integr
regul
dynam
equilibrium
exist
contractil
forc
tether
forc
transcellular
stress
fiber
format
activ
actomyosin
interact
along
cortic
actin
ring
disassembl
result
contractil
tension
induc
cell
round
contribut
cellcel
gap
format
fig
inhibit
cytoskelet
reorgan
attenu
barrier
dysfunct
contract
trigger
ec
regul
nmmlckcatalyz
mlc
phosphoryl
increas
actomyosin
atpas
activ
shift
equilibrium
fold
unfold
myosin
form
thu
provid
assembl
function
contractil
apparatu
cell
mylk
gene
chromosom
human
encod
three
protein
nmmlck
isoform
smooth
muscl
mlck
isoform
telokin
smooth
muscl
nmmlck
express
rel
low
level
present
togeth
shorter
smooth
muscl
isoform
wherea
nmmlck
detect
ec
exist
amino
acid
high
molecular
weight
protein
nmmlck
share
essenti
ident
catalyt
cam
regulatori
motif
smooth
muscl
mlck
contain
uniqu
amino
acid
ntermin
domain
compris
potenti
novel
ptm
site
inflammatori
agonist
vegf
thrombin
produc
rapid
increas
mlc
phosphoryl
reflect
coordin
nmmlck
activ
small
gtpase
rho
effector
rho
kinas
result
phosphoryl
therebi
inhibit
myosin
phosphatas
result
stabil
accumul
phosphoryl
mlc
aggreg
result
actomyosin
interact
ec
permeabl
significantli
attenu
mlck
rho
kinas
inhibitor
despit
clear
contribut
mlckrho
kinas
driven
increas
mlc
phosphoryl
tension
develop
increas
vascular
permeabl
mlckindepend
pathway
also
involv
regul
cellular
contract
protein
kinas
c
pkc
mediat
pathway
exert
promin
effect
barrier
regul
timeand
speciesspecif
manner
without
significantli
increas
mlc
phosphoryl
without
induc
format
actin
stress
fiber
alter
compon
endotheli
cytoskeleton
pkcmediat
increas
ec
permeabl
involv
phosphoryl
caldesmon
actin
myosin
calmodulinbind
protein
present
smooth
muscl
actomyosin
crossbridg
protein
ec
protein
phosphoryl
caldesmon
alter
smooth
muscl
crossbridg
activ
caldesmonmedi
regul
actomyosin
atpas
smooth
muscl
also
modifi
actin
crosslink
protein
filamin
gelsolin
although
filamin
particip
directli
barrier
regul
via
cam
kinas
ii
activ
effect
actin
cytoskelet
rearrang
regul
rho
famili
gtpase
therebi
provid
anoth
link
known
modul
ec
barrier
function
cytokin
tumor
necrosi
factor
tnfa
induc
slowonset
barrier
disrupt
cultur
ec
independ
mlck
activ
final
kinas
activ
also
link
contractil
regul
smooth
muscl
ec
migrat
lipopolysaccharid
lp
induc
ec
permeabl
mechan
exert
effect
unclear
may
involv
actinbind
protein
known
mitogenactiv
protein
kinas
mapk
target
whose
actinpolymerizationinhibit
activ
dramat
decreas
phosphoryl
associ
stress
fiber
develop
pulsatil
natur
blood
pressur
flow
expos
blood
vessel
constant
hemodynam
forc
form
ss
cyclic
stretch
cs
flow
blood
parallel
vessel
surfac
produc
fluid
ss
friction
blood
vessel
wall
contrast
cs
import
mechan
forc
gener
lung
circul
either
circul
blood
result
rhythmic
pulsatil
distens
arteri
wall
tidal
breath
endothelium
convert
mechan
stimuli
intracellular
signal
effector
cellular
function
includ
prolifer
migrat
remodel
apoptosi
permeabl
well
gene
express
cytoskeleton
key
structur
framework
ec
transmit
mechan
forc
lumin
ablumin
junction
surfac
interior
includ
cytoplasm
nucleu
focal
adhes
site
chang
mechan
stress
among
organ
bodi
lung
exist
highoxygen
environ
suscept
injuri
oxid
stress
cigarett
smoke
inhal
airborn
pollutantstoxin
oxid
gase
particul
matter
result
direct
lung
damag
well
activ
lung
inflammatori
respons
longterm
exposur
lung
higher
oxygen
tension
hyperoxia
observ
prematur
infant
critic
ill
patient
ventil
caus
oxid
stress
lung
injuri
thu
increas
ro
product
directli
link
inflammatori
lung
diseas
asthma
chronic
obstruct
pulmonari
diseas
ard
ro
essenti
normal
lungendotheli
function
imbal
redox
equilibrium
may
contribut
pulmonari
edema
imbal
oxid
produc
oxid
detoxifi
ie
chang
redox
equilibrium
appear
import
develop
variou
inflammatori
lung
diseas
increas
ro
product
directli
link
oxid
dna
protein
lipid
sugar
remodel
ecm
alter
mitochondri
respir
apoptosi
furthermor
increas
level
ro
implic
initi
signal
cascad
activ
transcript
factor
nfkb
chromatin
remodel
gene
express
proinflammatori
mediat
also
ro
gener
phagocyt
recruit
site
inflamm
excess
gener
ro
vascular
cell
major
caus
edema
lung
injuri
gener
ro
ro
signal
lung
endothelium
alter
vascular
permeabl
vivo
endotheli
monolay
despit
sever
potenti
sourc
ro
mitochondri
electron
transport
chain
cytochrom
enzym
xanthin
oxidas
nitric
oxid
synthas
myeloperoxidas
mpo
system
vascular
nadph
oxidas
famili
protein
shown
major
contributor
endotheli
ro
respons
hyperoxia
sinc
nadph
oxidas
mediat
superoxid
product
increas
endotheli
permeabl
varieti
agonist
cytokin
growth
factor
mechan
forc
alter
pulmonari
vascular
barrier
properti
serv
increas
vascular
permeabl
serin
proteas
thrombin
repres
ideal
model
examin
agonistmedi
lung
endotheli
activ
barrier
dysfunct
thrombin
evok
numer
ec
respons
regul
hemostasi
thrombosi
recogn
import
mediat
pathogenesi
ali
thrombin
increas
ec
leaki
macromolecul
ligat
proteolyt
cleav
extracellular
ntermin
domain
thrombin
receptor
member
famili
par
cleav
nterminu
act
tether
ligand
activ
receptor
initi
number
downstream
effect
includ
cytoskelet
rearrang
fig
vivo
studi
detail
event
follow
thrombin
infus
pulmonari
arteri
chronic
instrument
lung
lymph
sheep
model
initi
cascad
event
culmin
intravascular
coagul
inflamm
vascular
leak
natur
occur
agonist
cytokin
tnfa
promin
effect
earli
ali
caus
microthrombosi
elicit
cascad
inflammatori
signal
result
capillari
endotheli
product
pselectin
adhes
molecul
enhanc
leukocyteec
migrat
actin
reorgan
paracellular
gap
format
tnfa
also
increas
tyrosin
phosphoryl
vecadherin
lead
increas
paracellular
gap
human
lung
endothelium
much
less
known
prebcel
colonyenhanc
factor
pbef
rel
unknown
cytokin
identifi
via
function
genom
approach
novel
ali
candid
gene
pbef
also
known
visfatin
follow
identif
viscer
fat
hormon
nicotinamid
phosphoribosyltransferas
nampt
serv
ratelimit
compon
nad
biosynthesi
pathway
catalyz
convers
nicotinamid
phosphoribosylpyrophosph
nicotinamid
mononucleotid
demonstr
pbef
novel
biomark
sepsi
sepsisinduc
ali
genet
variant
confer
ali
suscept
furthermor
pbef
highli
express
polymorphonuclear
neutrophil
pmn
sepsi
subject
express
upregul
mechan
forc
inflammatori
cytokin
involv
ec
barrier
regul
explor
mechanist
particip
pbef
ali
vili
demonstr
recombin
human
pbef
direct
neutrophil
chemotact
factor
elicit
mark
increas
level
bronchoalveolar
lavag
bal
pmn
pmn
chemoattract
kc
intratrach
inject
mice
chang
accompani
modest
increas
lung
vascular
alveolar
permeabl
dramat
increas
bal
pmn
bal
protein
cytokin
level
tnfa
kc
observ
recombin
human
pbefand
vilichalleng
mice
wherea
heterozyg
pbef
mice
significantli
protect
reduc
bal
protein
level
bal
level
peak
inspiratori
pressur
expos
model
sever
vili
exhibit
significantli
reduc
express
viliassoci
gene
express
modul
role
reninangiotensin
system
pulmonari
vascular
regul
well
recogn
angiotensin
ii
key
compon
reninangiotensin
system
gener
primarili
angiotensinconvert
enzym
ace
angiotensin
effect
mediat
angiotensin
type
angiotensin
type
ii
receptor
express
normal
lung
pulmonari
endothelium
repres
major
site
ace
express
angiotensin
ii
product
homologu
ace
express
lung
inactiv
angiotensin
ii
lead
downstream
gener
angiotensin
act
receptor
induc
vasodilat
although
compon
reninangiotensin
system
implic
varieti
lung
diseas
includ
pulmonari
hypertens
fibrot
lung
diseas
system
strongli
link
pathophysiolog
pulmonari
vascular
leak
syndrom
exampl
serv
receptor
coronaviru
first
identifi
respons
sever
acut
respiratori
syndrom
mortal
rate
elderli
ace
serv
protect
role
ard
wherea
angiotensin
ii
mediat
lung
edema
injuri
associ
ard
role
ace
via
angiotensin
ii
bradykinin
ali
propos
reduct
ace
activ
captopril
attenu
inflammatori
respons
apoptosi
wherea
block
bradykinin
receptor
attenu
antiinflammatori
antiapoptot
effect
captopril
captopril
attenu
ace
activ
necrosi
indic
inflamm
apoptosi
vili
due
acemedi
ang
angiotensin
ii
product
new
blood
vessel
format
angiogenesi
defin
gener
new
capillari
ec
either
sprout
split
preexist
vessel
sprout
angiogenesi
involv
ec
detach
basement
membran
migrat
subsequ
prolifer
tube
format
final
function
matur
new
vessel
vegf
key
vasculogenesi
mice
lack
vegf
receptor
fail
develop
fulli
function
blood
vessel
inhibit
vegf
promis
therapeut
strategi
manag
patient
advanc
malign
pulmonari
hypertens
devast
diseas
mani
similar
neoplast
process
character
aberr
angiogenesi
vegf
serv
target
pulmonari
hypertens
vegf
increas
ec
permeabl
origin
name
vascular
permeabl
factor
profound
effect
vascular
barrier
function
vegf
level
highest
lung
plasma
vegf
level
increas
patient
ard
compar
group
vegf
increas
cytosol
calcium
level
level
mlc
phosphoryl
high
dose
vegf
inhibit
decreas
ec
permeabl
addit
angiogen
factor
barrierregulatori
properti
includ
angiopoietin
angiopoietin
critic
normal
vascular
develop
angiopoietin
famili
compops
vascular
growth
factor
ligand
famili
tyrosin
kinas
select
express
vascular
endothelium
vegf
induc
ec
differenti
migrat
wherea
angiopoietin
stabil
vascular
network
angiopoietin
angiopoietin
modul
ec
permeabl
alter
state
aj
specif
inhibit
vascular
leakag
respons
vegf
barrierdisrupt
agent
well
promot
vessel
matur
angiopoietin
antagon
angiopoietin
promot
barrier
dysregul
block
abil
angiopoietin
activ
receptor
understand
mechan
barrier
dysfunct
offer
advantag
design
therapeut
strategi
target
barrierintegr
preserv
revers
establish
barrier
dysfunct
restor
vascular
integr
prior
last
decad
permeabilityreduc
strategi
primarili
consist
cyclic
amp
camp
augment
produc
modest
barrier
enhanc
recent
number
barrierpromot
agent
identifi
share
common
signal
transduct
mechan
distinct
camp
signal
target
endotheli
actin
cytoskeleton
facilit
barrierrestor
process
dynam
process
actin
polymer
allow
rapid
reorgan
actin
structur
profound
function
consequ
barrier
regul
highli
depend
exact
spatial
locat
actin
rearrang
occur
either
barrierdisrupt
cytosol
stress
fiber
barrierenhanc
thicken
cortic
actin
ring
demonstr
quiescent
ec
phenotyp
character
cortic
actin
ring
stress
fiber
structur
favor
cellcel
adhes
cellmatrix
tether
conceptu
paradigm
wherebi
barrier
recoveri
edemagen
agonist
involv
develop
cortic
actin
ring
anchor
cellular
junction
care
choreograph
poorli
understood
gapclos
process
via
format
rac
gtpasedepend
lamellipodi
protrus
paracellular
space
activ
ec
fig
within
lamellipodia
signal
transduc
actinbind
protein
nmmlck
cortactin
phosphoryl
mlc
spatialspecif
cellular
locat
lamellipodia
also
requir
format
focal
adhes
regul
cytoskeleton
critic
establish
linkag
actin
cytoskeleton
target
effector
restor
cellcel
adhes
cellmatrix
adhes
process
essenti
restor
endotheli
barrier
respons
exposur
agonist
sphingosin
hepatocyt
growth
factor
hgf
simvastatin
activ
protein
c
apc
atp
oxid
phopholipid
hyaluaron
central
event
activ
small
gtpase
rac
follow
ligat
barrierprotect
receptor
drive
cortic
actin
remodel
lamellipodia
format
fig
addit
lamellipodia
increas
actin
polymer
cell
peripheri
ie
cortic
actin
ring
occur
increas
forc
driven
actinbind
protein
cortactin
nmmlck
also
transloc
spatial
defin
region
like
lamellipodia
format
rac
gtpasedepend
increas
level
cortic
actin
follow
exposur
multipl
barrierenhanc
level
ss
potent
barrierenhanc
agonist
includ
hgf
atp
simvastatin
apc
prostaglandin
e
oxid
phospholipid
oxpapc
tabl
observ
serv
highlight
import
cellular
locat
cytoskelet
protein
maintain
enhanc
ec
barrier
function
cortactin
directli
interact
nmmlck
associ
increas
src
tyrosin
phosphoryl
either
cortactin
nmmlck
rac
activ
conjunct
aktmedi
phosphoryl
event
known
involv
ec
prolifer
migrat
ec
barrier
enhanc
aktinduc
phosphoryl
receptor
import
barrier
enhanc
produc
high
molecular
weight
hyaluronan
receptor
induc
rapid
potent
endotheli
barrier
enhanc
reduct
number
central
actin
stress
fiber
enhanc
cortic
actin
format
stabil
cellcel
junction
attenu
endotoxininduc
pulmonari
edema
mice
canin
model
injuri
simvastatin
patient
cholesterolreduc
statin
regimen
exhibit
improv
vascular
function
hmgcoa
reductas
inhibitor
mitig
vegf
signal
rhoa
inhibit
rac
activ
vitro
simvastatin
pretreat
protect
ec
thrombininduc
stress
fiber
format
barrier
dysfunct
atp
g
g
protein
atp
receptor
atp
induc
endotheli
barrier
enhanc
racdepend
cytoskelet
rearrang
reduct
number
central
actin
stress
fiber
increas
cortic
actin
format
vivo
nonhyrolyz
atp
protect
mice
endotoxininduc
lung
injuri
hgf
oxpapc
accentu
peripher
factin
uniqu
ziplik
configur
novel
interact
focal
adhes
aj
complex
vivo
oxpapc
protect
rat
mechanicalstressinduc
lung
injuri
mntx
mopr
inhibit
receptor
pretreat
mopr
antagonist
protect
ec
thrombinand
lpsinduc
barrier
dysfunct
moprindepend
antagon
involv
inhibit
rhoadepend
receptor
fda
recent
approv
mntx
treatment
postop
ileu
may
rapidli
translat
treatment
pulmonari
edema
antipbef
neutral
antibodi
extracellular
pbef
pbef
significantli
upregul
lung
injuri
extracellular
releas
pbef
promot
endotheli
barrier
dysfunct
neutrophil
extravas
antipbef
neutral
antibodi
target
extracellular
pbef
without
alter
benefici
intracellular
pbef
protect
lung
ventilatorinduc
lung
injuri
mice
adheren
junction
activ
protein
c
endotheli
cell
endotheli
protein
c
receptor
filament
actin
hepatocyt
growth
factor
coenzym
lipopolysaccharid
mitogenactiv
protein
kinas
myosin
light
chain
kinas
methylnaltrexon
mu
opioid
receptor
phosphatidylinositol
prebcel
colonyenhanc
factor
protein
kinas
c
sphingosin
vascular
endotheli
growth
factor
histor
cyclic
nucleotid
repres
sole
strategi
retard
edema
phase
observ
inflammatori
lung
syndrom
possibl
via
campdepend
protein
kinas
phosphoryl
protein
mlck
inhibit
factin
reorgan
examin
nmmlck
molecular
target
involv
increas
lung
epitheli
ec
barrier
permeabl
util
genet
engin
mice
complementari
strategi
reduc
nmmlck
activ
express
mlck
inhibit
membraneperm
oligopeptid
pik
silenc
nmmlck
express
lung
significantli
attenu
lpsinduc
lung
permeabl
inflamm
also
target
pulmonari
vessel
util
ace
antibodyconjug
liposom
nmmlck
small
interf
rna
sirna
cargo
murin
vili
model
signific
attenu
vili
furthermor
nmmlck
knockout
mice
significantli
protect
expos
model
sever
vili
thu
multidimension
cytoskelet
protein
nmmlck
repres
attract
target
reduc
lung
vascular
permeabl
lung
inflamm
critic
ill
sphingolipid
result
phosphoryl
sphingosin
product
sphingomyelinas
catabol
sphingomyelin
catalyz
sphingosin
kinas
ligat
famili
receptor
known
receptor
also
term
endotheli
differenti
gene
edg
receptor
promin
effect
vasculatur
promot
ec
mitogenesi
chemotaxi
angiogenesi
earlier
studi
first
demonstr
potent
ec
chemoattract
serum
link
receptor
ligat
enhanc
vascular
barrier
regul
demonstr
physiolog
dose
induc
ec
activ
mark
cytoskelet
rearrang
stabil
lung
ec
barrier
function
vitro
novel
function
particular
relev
clinic
medicin
thrombocytopenia
well
known
associ
increas
vascular
leak
although
mechan
effect
unknown
demonstr
activ
platelet
import
sourc
directli
enhanc
barrier
function
via
receptor
ligat
platelet
contain
signific
level
sphingosin
kinas
reduc
level
sphingosin
lyas
therebi
serv
enrich
sourc
barrierpromot
ligat
barrierenhanc
g
proteincoupl
receptor
also
known
increas
rac
gtpase
activ
cytosol
calcium
level
aggreg
key
barrierregulatori
signal
compon
caveolinrich
lipid
raft
includ
rac
gtpase
target
serthr
kinas
pak
downstream
target
cofilin
actinbind
protein
nmmlck
cortactin
cabl
pak
cofilin
allow
polymerizationdepolymer
cycl
occur
thu
facilit
rearrang
actin
primarili
transcytoplasm
primarili
cortic
spatial
distinct
organ
cortic
actin
cellular
ring
process
integr
ec
barrier
function
increas
mlc
phosphoryl
within
peripher
distribut
within
cortic
actin
ring
provid
strength
spatial
direct
scaffold
forc
enhanc
cellcel
tether
describ
via
atom
forc
microscopi
immunofluoresc
studi
demonstr
overexpress
green
fluoresc
proteinnmmlck
distribut
along
cytoplasm
actin
fiber
rapidli
transloc
cortic
region
cell
treatment
rapidli
catalyz
mlc
phosphoryl
addit
confoc
microscopi
studi
show
ec
challeng
demonstr
coloc
nmmlck
key
actinbind
ec
barrierregulatori
protein
cortactin
interact
cortactin
nmmlck
decreas
cortactinstimul
actin
polymer
essenti
barrier
protect
src
involv
pathway
tyrosin
kinas
cabl
like
involv
cytoskelet
rearrang
produc
increas
linkag
actin
aj
compon
well
phosphoryl
focaladhesionrel
protein
paxillin
fak
transloc
protein
ec
peripheri
implic
cellcel
adhes
chang
part
mechan
barrier
enhanc
potenti
util
restor
lung
water
balanc
patient
inflammatori
injuri
underscor
studi
involv
smalland
largeanim
model
ali
provid
dramat
attenu
lpsmediat
lung
inflamm
permeabl
mice
treat
significantli
less
histolog
evid
inflammatori
changeslung
injuri
decreas
neutrophil
alveol
bal
decreas
lung
mpo
activ
interestingli
mice
treat
intratrach
administr
lp
also
show
attenu
renal
inflammatori
respons
compar
control
measur
tissu
mpo
activ
evan
blue
dye
extravas
measur
capillari
leak
also
protect
intrabronchi
lpsinduc
ali
concomit
vili
canin
model
decreas
shunt
fraction
decreas
bal
protein
decreas
extravascular
lung
water
improv
oxygen
use
largeanim
canin
model
allow
investig
region
lung
chang
ali
effect
chang
comput
tomographi
scan
anim
subject
lpsvili
found
anim
treat
dramat
improv
alveolar
air
content
decreas
edema
lung
region
addit
vivo
studi
found
protect
vili
murin
model
assess
evan
blue
dye
extravas
also
evalu
potenti
role
amelior
lung
ischemiareperfus
injuri
common
sequela
lung
transplant
character
alveolar
damag
edema
inflamm
donor
lung
signific
caus
transplant
failur
util
rat
model
ischemiareperfus
injuri
pulmonari
arteri
ligat
reperfus
determin
rat
pretreat
exhibit
reduc
lung
vascular
permeabl
inflamm
compar
control
lung
mpo
activ
index
parenchym
leukocyt
infiltr
level
also
attenu
anim
expos
ischemiareperfus
injuri
togeth
find
suggest
may
serv
effect
permeabilityreduc
agent
divers
condit
share
element
lung
inflammatori
burden
despit
profound
attract
therapeut
agent
target
endothelium
highperm
state
sever
attribut
limit
potenti
util
permeabilityreduc
strategi
affin
ligat
receptor
intratrach
implic
caus
pulmonari
edema
via
endotheli
epitheli
barrier
disrupt
also
caus
bradycardia
via
ligat
cardiac
receptor
find
gener
increas
interest
deriv
natur
immunosuppress
myriocin
recent
describ
immunosuppress
agent
caus
peripher
lymphopenia
inhibit
cellular
egress
lymphoid
tissu
structur
similar
ident
phosphoryl
sphingosin
kinas
agonist
receptor
characterist
prompt
investig
effect
ec
barrier
function
superior
efficaci
compar
mycophenol
mofetil
prevent
renal
transplant
reject
phase
iii
clinic
trial
immunosuppress
multipl
sclerosi
patient
clinic
avail
make
attract
potenti
mediat
ec
barrier
function
patient
ali
vivo
studi
demonstr
intraperiton
administ
protect
intratrach
administ
lp
murin
model
ali
measur
evan
blue
dye
extravas
mechan
ec
barrier
enhanc
diverg
mechan
describ
sever
way
includ
delay
kinet
rise
total
energi
requir
ter
compar
decreas
express
receptor
prevent
increas
ter
partial
alter
ter
increas
unlik
result
threonin
phosphoryl
receptor
inhibit
phosphatidylinositol
prevent
ec
barrier
enhanc
furthermor
caus
increas
intracellular
calcium
level
mlc
phosphoryl
cytoskelet
rearrang
seen
respons
downregul
rac
cortactin
use
sirna
attenu
barrierenhanc
effect
although
receptor
agonist
mechan
barrier
enhanc
distinct
requir
receptor
current
pursu
novel
fti
analogu
use
inflammatori
lung
injuri
model
anoth
class
promin
barrierprotect
agonist
intens
scrutini
statin
famili
compound
known
coenzym
reductas
hmgcoa
reductas
inhibitor
drug
inhibit
cholesterol
synthesi
liver
commonli
use
clinic
practic
lipidlow
agent
prevent
acut
coronari
event
plethora
report
demonstr
benefit
statin
therapi
entir
attribut
decreas
serum
cholesterol
level
interest
effect
statin
endotheli
function
ali
evergrow
bodi
literatur
demonstr
improv
outcom
patient
sepsi
treat
statin
decreas
mortal
bacterem
patient
admit
hospit
statin
therapi
retrospect
studi
human
patient
multipl
organ
dysfunct
syndrom
found
receiv
statin
significantli
lower
mortal
hospit
mortal
compar
match
control
receiv
statin
therapi
anim
studi
suggest
dramat
improv
surviv
mice
treat
simvastatin
prior
initi
sepsi
cecal
ligat
punctur
compar
mice
pretreat
simvastatin
pursu
mechan
statin
action
endothelium
found
simvastatin
attenu
thrombininduc
stress
fiber
format
paracellular
gap
format
barrier
dysfunct
coincub
mevalon
product
hmgcoa
reductas
activ
elimin
protect
effect
simvastatin
thrombininduc
ec
permeabl
indic
effect
due
hmgcoa
reductas
inhibit
involv
either
intracellular
increas
camp
level
increas
level
endotheli
nitric
oxid
synthas
statin
inhibit
geranylgeranyl
small
gtpase
essenti
gtpase
interact
cell
membran
transloc
small
gtpase
rac
rho
plasma
membran
ec
pretreat
simvastatin
prevent
thrombininduc
transloc
rho
plasma
membran
simvastatin
found
confer
greater
protect
thrombininduc
barrier
dysfunct
rho
inhibit
alon
rac
inhibit
may
protect
via
decreas
activ
nadph
oxidas
result
superoxid
induc
barrier
dysfunct
also
found
import
simvastatininduc
ec
barrier
protect
simvastatin
pretreat
result
reduc
diphosphoryl
mlc
level
reduc
number
stress
fiber
increas
rac
gtpase
activ
cortactin
transloc
ec
peripheri
increas
cortic
actin
decreas
paracellular
gap
format
thrombin
treatment
unlik
simvastatin
caus
increas
baselin
ter
simvastatin
elicit
chang
ec
gene
express
downregul
caldesmon
thrombin
receptor
well
upregul
integrin
b
known
function
cellcel
adhes
rac
gef
may
regul
rho
gtpase
activ
import
new
protein
synthesi
barrier
protect
effect
simvastatin
establish
elimin
protect
effect
coincub
ec
simvastatin
protein
synthesi
inhibitor
cycloheximid
vivo
data
intratracheallp
murin
model
ali
support
vitro
find
simvastatin
protect
ec
barrier
function
marker
inflammatori
lung
injuri
compar
control
decreas
bal
neutrophil
count
mpo
activ
decreas
vascular
permeabl
mark
reduct
inflammatori
histolog
chang
investig
gene
express
lung
tissu
mice
pretreat
simvastatin
lpsinduc
model
ali
found
simvastatin
caus
differenti
regul
sever
famili
gene
includ
inflammatori
immun
respons
gene
well
nfkb
regul
cell
adhes
gene
simvastatin
may
prove
clinic
relev
treat
ali
ali
typic
prolong
cours
treatment
simvastatin
along
trajectori
ill
may
benefici
end
blind
random
control
clinic
trial
simvastatin
ali
current
way
atp
found
abund
ec
microenviron
particip
ec
barrier
regul
constitut
releas
atp
across
ec
apic
membran
basal
condit
atp
reduc
ec
albumin
permeabl
concentrationdepend
manner
ec
varieti
origin
includ
porcin
aorta
pulmonari
arteri
bovin
aorta
human
umbil
vascular
endotheli
cell
mechan
atpinduc
ec
barrier
enhanc
involv
g
g
protein
involv
adenosin
receptor
increas
pkc
activ
increas
cyclic
gmp
level
howev
atpinduc
decreas
ec
permeabl
found
involv
phospholipas
c
signal
pathway
well
alter
ec
mlc
phosphoryl
demonstr
atp
produc
ca
mapkindepend
increas
cellcel
interfac
vecadherin
stain
increas
thick
continu
zona
occluden
tj
mediat
part
via
campindepend
activ
protein
kinas
pka
also
note
atp
produc
biphas
effect
mlc
phosphoryl
initi
increas
follow
decreas
level
phosphoryl
mlc
howev
delay
decreas
level
phosphoryl
mlc
prevent
phosphatas
inhibitor
emphas
import
gproteinmedi
phosphatas
activ
atpinduc
decreas
mlc
phosphoryl
atpinduc
barrier
enhanc
similar
well
hgf
apc
etc
atpmedi
barrier
enhanc
requir
racdepend
cytoskelet
rearrang
decreas
number
central
actin
stress
fiber
increas
cortic
distribut
actin
peripher
mlc
phosphoryl
cortactin
transloc
cortic
actin
ring
addit
rapid
transient
increas
mlc
diphosphoryl
observ
atp
stimul
phosphoryl
mlc
local
cell
peripheri
stark
contrast
central
stressfiberassoci
phosphoryl
mlc
seen
ec
treat
thrombin
extens
vitro
studi
effect
purinerg
stimul
assess
murin
model
ali
intratrach
administ
lp
atp
rapidli
degrad
intravascularli
nonhydrolyz
analogu
atpg
use
vivo
studi
mice
given
atpg
intraven
concomit
intratrach
administr
lp
protect
lpsinduc
ali
compar
control
assess
neutrophil
infiltr
mpo
activ
atpg
also
attenu
lung
microvascular
permeabl
elicit
lp
decreas
bal
protein
decreas
evan
bluealbumin
extravas
mice
treat
atpg
compar
control
atpgstreat
anim
also
protect
lpsinduc
decreas
bodi
weight
seen
control
mice
addit
vitro
studi
found
atpg
alon
produc
increas
ter
ec
also
show
delay
protect
reduct
ter
caus
lp
alter
vascular
permeabl
requisit
step
angiogen
process
first
report
hgf
wellknown
angiogen
factor
like
potent
ec
barrierprotect
agonist
act
via
stabil
ec
actin
cytoskeleton
hgfmediat
ec
protect
barrierdisrupt
effect
thrombin
evolv
via
increas
rac
activ
involv
racspecif
gef
well
decreas
rho
activ
increas
phosphoryl
hgf
signal
via
tyrosin
kinas
receptor
cmet
serv
recruit
key
transactiv
receptor
caveolinenrich
microdomain
cem
lipid
raft
experi
use
sirna
cmet
found
import
hgfinduc
increas
ec
ter
furthermor
pretreat
ec
ceminterf
compound
methylbcyclodextran
also
prevent
hgfinduc
increas
ter
addit
rac
activ
hgf
found
requir
cem
format
cmet
mous
model
lpsinduc
ali
hgf
protect
marker
lung
inflamm
effect
note
knockout
mice
signal
mechan
involv
hgfinduc
ec
barrier
enhanc
complex
import
role
cmet
cem
format
hgf
produc
racdepend
increas
level
cortic
actin
cortactin
transloc
cortic
level
phosphoryl
mlc
mechanist
studi
found
hgfinduc
ec
barrier
enhanc
critic
involv
activ
distinguish
mechan
hgfinduc
barrier
enhanc
import
role
mapk
erk
pkc
hgfinduc
ec
barrier
enhanc
attent
role
improv
cellcel
cellmatrix
adhes
elicit
hgf
found
hgf
produc
increas
bcatenin
local
ec
peripheri
alongsid
cortic
actin
increas
associ
bcatenin
vecadherin
cell
signal
effector
hgf
erk
pkc
found
converg
phosphoryl
glycogen
synthas
regul
associ
bcatenin
cadherin
therebi
control
cellcel
adhes
apc
serin
proteas
modul
coagul
inflamm
food
drug
administr
approv
xigri
recombin
human
apc
rhapc
also
known
drotrecogin
alfa
activ
treatment
sever
sepsi
adult
random
trial
found
surviv
benefit
treat
patient
sever
sepsi
involv
ali
system
increas
vascular
permeabl
effect
apc
pulmonari
ec
permeabl
intrigu
interest
effect
anticoagul
apc
ec
permeabl
also
relat
welldescrib
role
procoagul
thrombin
ec
barrier
disrupt
furthermor
mechan
surviv
benefit
impart
treatment
rhapc
unclear
apc
given
human
subject
set
endotoxin
infus
improv
hemodynam
antiinflammatori
antithrombot
effect
suggest
differ
mechan
may
involv
demonstr
apc
prevent
abl
revers
thrombininduc
increas
permeabl
apc
also
increas
mlc
phosphoryl
level
actin
ec
peripheri
decreas
number
f
central
stress
fiber
barrierenhanc
effect
apc
found
mediat
activ
similar
barrierenhanc
effect
simvastatin
hgf
endotheli
protein
c
receptor
epcr
critic
apcinduc
barrier
enhanc
mlc
phosphoryl
furthermor
epcrmedi
transactiv
receptor
via
essenti
involv
direct
interact
epcr
receptor
novel
pathway
apcinduc
ec
barrier
enhanc
may
contribut
significantli
surviv
benefit
offer
rhapc
patient
sever
sepsi
recent
work
focus
apc
anim
model
ali
use
rat
model
intestin
ischemiareperfus
injuryinduc
ali
investig
found
apc
treatment
prior
reperfus
attenu
subsequ
pulmonari
edema
accompani
fewer
neutrophil
histolog
examin
mark
improv
histolog
appear
compar
anim
receiv
apc
addit
rat
treat
apc
prior
intestin
reperfus
lower
serum
level
tnfa
ddimer
compar
control
investig
apc
mous
model
vili
found
apc
pretreat
protect
vili
caus
high
tidal
volum
ventil
mice
pretreat
apc
exhibit
signific
reduct
bal
protein
evan
blue
dye
extravas
compar
control
oxid
phospholipid
deriv
oxid
lowdens
lipoprotein
focu
much
investig
area
vascular
injuri
inflamm
increas
level
note
ali
oxid
phospholipid
result
oxid
oxpapc
activ
mapk
erk
cjun
ntermin
kinas
downstream
target
increas
activ
pkc
pka
src
kinas
process
involv
oxpapcmedi
ec
barrier
enhanc
wherea
rho
rho
kinas
erk
involv
furthermor
oxpapc
result
phosphoryl
actinbind
protein
cofilin
well
phosphoryl
focal
adhes
protein
fak
paxillin
indic
oxpapc
may
affect
ec
actin
cytoskeleton
cellcel
adhes
oxpapc
protect
ec
barrier
dysfunct
vitro
thrombin
lp
stimu
lation
oxpapc
accentu
peripher
factin
uniqu
ziplik
configur
result
continu
focal
adhes
accumul
bcatenin
signal
pathway
involv
oxpapcmedi
endotheli
barrier
protect
involv
rac
rac
effector
upstream
gef
bpix
actinbind
protein
cortactin
oxpapc
found
caus
novel
interact
focal
adhes
aj
complex
process
mediat
associ
paxillin
bcatenin
depend
upon
rac
vivo
studi
shown
intraven
oxpapc
deliveri
result
signific
attenu
lpsinduc
inflamm
rat
model
vili
oxpapc
protect
ec
mechanicalstressinduc
injuri
via
cytoskelet
rearrang
chang
rho
rac
activ
remain
potenti
therapi
profound
pulmonari
edema
associ
inflammatori
state
methylnaltrexon
mntx
peripher
restrict
mu
opioid
receptor
mopr
antagonist
recent
approv
food
drug
administr
treatment
postop
ileu
also
recent
found
work
synergist
bevacizumab
inhibit
vegfinduc
pulmonari
ec
prolifer
migrat
antagonist
mopr
interest
potenti
ec
barrierenhanc
agent
barrierdisrupt
properti
mopr
agonist
morphin
pretreat
human
pulmonari
microvascular
ec
mm
mntx
found
protect
decreas
ter
caus
mopr
agonist
morphin
damgo
also
protect
barrierdisrupt
effect
thrombin
lp
act
independ
mopr
mntx
augment
barrierenhanc
effect
ec
pretreat
naloxon
charg
mopr
antagonist
protect
morphin
damgoinduc
barrier
disrupt
protect
barrier
disrupt
caus
thrombin
lp
data
togeth
observ
sirna
target
mopr
minim
effect
mntxinduc
protect
thrombin
lp
suggest
protect
effect
mntx
attribut
mopr
antagon
alon
experi
found
mntx
confer
barrierprotect
effect
inhibit
associ
rhoaactiv
gef
receptor
result
rhoa
activ
caus
barrierdisrupt
agent
complementari
vivo
experi
found
intraven
administr
mntx
ali
establish
via
intratrach
administr
lp
protect
ali
h
assess
histolog
examin
bal
protein
tnfa
level
note
alreadi
pbef
biomark
sepsi
sepsisinduc
ali
intratrach
inject
recombin
pbef
mice
result
increas
lung
inflamm
vascular
permeabl
indic
extracellular
pbef
promot
endotheli
barrier
dysfunct
intracellular
pbef
may
contrast
benefici
respons
ali
function
via
effect
cell
apoptosi
neutrophil
sepsi
patient
increas
express
pbef
promot
cell
surviv
enzymat
process
nad
biosynthesi
via
nicotinamid
phosphoribosyltransferas
nampt
activ
featur
cancer
cell
util
prevent
cell
death
nampt
inhibitor
current
trial
cancer
drug
promot
apoptosi
thu
pbef
therapi
complic
intracellular
pbef
appear
benefici
effect
cell
promot
cell
surviv
wherea
extracellular
pbef
appear
induc
inflammatori
respons
specif
target
extracellular
pbef
may
induc
deleteri
cellular
respons
gener
neutral
antibodi
pbef
act
molecular
spong
extracellular
pbef
without
alter
intracellular
pbef
function
may
benefici
cell
use
mous
model
lung
injuri
demonstr
antipbef
neutral
antibodi
significantli
protect
lung
vili
reduc
avail
extracellular
pbef
sensit
lung
endothelium
studi
implic
pbef
key
inflammatori
mediat
intim
involv
develop
sever
ventilatorinduc
ali
demonstr
antipbef
neutral
antibodi
potenti
clinic
util
variou
molecul
particip
activ
inflamm
ali
serv
indic
progress
normal
patholog
biolog
process
provid
import
tool
detect
diseas
support
diagnost
therapeut
decis
ideal
vascular
biomark
strong
correl
presenceabs
diseas
state
clinic
outcom
provid
predict
point
intervent
slow
revers
diseas
furthermor
indic
specif
biomark
may
allow
custom
therapi
effect
differ
phase
diseas
new
research
novel
understand
molecular
mechan
ali
reveal
abund
excit
new
biomark
high
potenti
valu
prognost
tool
tabl
cofactor
thrombininduc
activ
protein
c
anticoagul
pathway
reduc
plasma
thrombomodulin
level
predict
higher
mortal
wors
system
dysfunct
inhibitor
plasminogen
activ
plasma
level
increas
predict
death
marker
ec
activ
adhes
molecul
level
increas
predict
death
cytokin
inflamm
level
increas
predict
death
cytokin
inflamm
secret
extracellular
pbef
upon
mechan
stress
induc
pulmonari
edema
neutrophil
extravas
mice
intercellular
adhes
interleukin
plasminogen
activ
solubl
intercellular
adhes
import
sphingolipid
maintain
physiolog
vascular
integr
well
establish
thrombocytopenia
clinic
condit
defici
number
circul
platelet
associ
increas
vascular
leak
via
unknown
mechan
activ
platelet
import
sourc
contain
signific
level
sphingosin
kinas
reduc
level
sphingosin
lyas
therebi
serv
enrich
sourc
barrierpromot
directli
enhanc
barrier
function
via
ligat
although
role
physiolog
concentr
critic
maintain
normal
endotheli
barrier
function
differenti
ligat
receptor
differenti
respons
contrast
ligat
ligat
induc
endotheli
barrier
dysfunct
via
activ
rhodepend
actin
stress
fiber
cellcel
gap
format
recent
discov
cultur
ec
challeng
barrierdisrupt
agent
induc
tyrosin
nitrat
receptor
releas
media
microparticl
exosom
occurr
protein
tyrosin
nitrat
diseas
condit
firmli
establish
repres
shift
physiolog
signal
action
oxid
potenti
pathogen
pathway
protein
tyrosin
nitrat
irrevers
ptm
mediat
reactiv
nitrogen
speci
process
suggest
regulatori
function
protein
undergo
phosphoryl
signal
transduct
cascad
might
serious
compromis
peroxynitritepromot
nitrat
explor
potenti
biomark
observ
immunoblot
analysi
serum
mice
expos
variou
model
vascular
injuri
signific
tyrosinenitr
express
addit
examin
serum
patient
sepsi
ali
discov
tyrosinenitr
receptor
correl
diseas
progress
therefor
data
indic
tyrosinenitr
receptor
releas
challeng
ec
microparticl
serv
novel
biomark
vascular
injuri
variou
diseas
model
famili
pmn
chemotact
cytokin
known
cxc
chemokin
describ
character
includ
groa
grob
grog
granulocyt
chemotact
peptid
gcp
chemokin
produc
human
alveolar
macrophag
contain
glutamylleucylarginin
elr
motif
critic
neutrophil
bind
chemotact
function
present
biolog
signific
concentr
bal
fluid
patient
ard
track
pmn
concentr
although
groa
concentr
higher
concentr
predomin
chemoattract
ard
bal
fluid
via
highaffin
bind
cxc
chemokin
receptor
human
pmn
unlik
groa
grob
grog
highaffin
bind
bind
either
receptor
high
affin
presenc
system
inflammatori
process
sever
sepsi
tonic
downregul
function
receptor
predomin
thu
multipl
neutrophil
chemotact
factor
produc
human
appear
small
group
particularli
relev
patient
ard
cognat
receptor
domin
receptorligand
pair
also
bind
circul
highaffin
polyclon
autoantibodi
natur
therefor
prevent
bind
cxc
chemokin
receptor
pmn
autoantibodi
present
lung
fluid
patient
atrisk
ard
well
patient
onset
ard
ratio
autoantibodi
cytokin
complex
significantli
higher
onset
ard
patient
risk
ard
addit
patient
ard
elev
complex
ratio
like
die
patient
lower
concentr
complex
thu
complex
ratio
lung
fluid
sampl
reveal
lung
fluid
protein
concentr
predict
develop
ard
patient
atrisk
also
predict
mortal
patient
ard
protein
c
pathway
one
import
regul
blood
coagul
serv
critic
link
coagul
inflamm
sepsi
ali
protein
c
vitaminkdepend
plasma
glycoprotein
synthes
liver
circul
twochain
biolog
inact
zymogen
transform
activ
form
apc
thrombomodulinthrombin
complex
cell
surfac
apc
suppress
thrombin
format
proteolyt
inactiv
coagul
factor
va
viiia
membranebound
epcr
potenti
activ
recent
evid
suggest
addit
anticoagul
effect
apc
also
antiinflammatori
properti
thu
protein
c
pathway
import
control
modul
coagul
inflamm
apc
inhibit
product
tnfa
via
nfkb
activ
monocyt
ec
inhibit
neutrophil
activ
chemotaxi
interact
cellsurfac
receptor
similar
epcr
decreas
protein
c
activ
pulmonari
vascular
endothelium
surfac
may
contribut
widespread
microvascular
thrombosi
occur
acut
injur
lung
may
also
proinflammatori
proapoptot
administr
apc
attenu
experiment
sepsisinduc
lung
injuri
human
studi
infus
apc
h
prior
h
administr
intraven
inject
lp
prevent
lpsinduc
increas
tissu
factor
express
thrombin
format
plasma
lp
inject
well
circul
level
tnfa
marker
inflamm
loss
thrombomodulin
epcr
cell
surfac
result
decreas
abil
activ
protein
c
phenomenon
implic
pathogenesi
sepsi
lung
injuri
releas
protein
c
pathway
compon
thrombomodulin
epcr
plasma
report
experiment
sepsi
model
clinic
studi
plasma
protein
c
level
reduc
patient
sever
sepsi
patient
meet
criteria
acquir
protein
c
defici
low
level
protein
c
associ
ventil
depend
higher
preval
ard
correl
higher
mortal
anoth
studi
demonstr
patient
sever
sepsi
vari
markedli
abil
gener
apc
modul
coagul
inflamm
activ
protein
c
critic
mechan
pathogenesi
sepsi
ali
protein
c
level
thrombomodulin
level
lower
earli
cours
ali
reduc
plasma
protein
c
thrombomodulin
level
associ
higher
mortal
nonpulmonari
organ
system
dysfunct
combin
low
level
protein
c
predictor
high
level
plasminogen
activ
confer
even
higher
risk
mortal
prognost
valu
protein
c
thrombomodulin
alter
exclus
patient
coexist
sepsi
balanc
activ
coagul
activ
fibrinolysi
like
import
determin
amount
durat
fibrin
deposit
injur
lung
fibrinolyt
system
profoundli
alter
patient
aliard
system
alveolar
compart
plasminogen
activ
pa
regul
fibrinolysi
dissolut
fibrin
clot
modul
convers
plasminogen
plasmin
major
fibrinolyt
enzym
upregul
major
inhibitor
fibrinolysi
appear
play
primari
role
shift
profibrinolyt
antifibrinolyt
phenotyp
varieti
cell
type
includ
ec
indic
risk
factor
ali
sepsi
two
form
pa
urokinasetyp
pa
upa
tissuetyp
pa
tpa
upa
cellsurfac
protein
respons
activ
fibrinolysi
tissu
level
wherea
tpa
solubl
protein
activ
intravascular
fibrinolysi
two
major
endogen
pa
inhibitor
identifi
produc
platelet
endotheli
mesotheli
epitheli
cell
includ
lung
major
pa
inhibitor
plasma
extravascular
fluid
implic
fibrinolyt
defect
associ
ali
human
lung
ec
isol
patient
ard
constitut
express
greater
level
control
lower
fibrinolyt
potenti
measur
pa
ratio
limit
aliard
clinic
studi
reduc
fibrinolyt
capac
increas
upa
activ
note
ard
patent
level
higher
pulmonari
edema
fluid
plasma
aliard
patient
correl
mortal
patient
ali
ard
varieti
strategi
explor
develop
inhibitor
might
therapeut
use
aliard
diseas
associ
high
level
cardiovascular
diseas
intercellular
adhes
adhes
molecul
constitut
express
normal
lung
critic
particip
pulmonari
innat
immun
solubl
repres
circul
form
constitut
express
induc
cell
surfac
differ
cell
line
structur
belong
immunoglobulin
superfamili
serv
counterreceptor
leukocyt
integrin
interact
present
ec
facilit
leukocyt
adhes
migrat
across
endothelium
howev
bind
lfa
inhibit
lymphocyt
attach
ec
found
bal
fluid
releas
induc
sever
cytokin
variou
factor
includ
tnfa
interferong
angiotensin
ii
via
proteolyt
cleavag
direct
transcript
messeng
rna
studi
correl
level
diseas
led
identif
marker
diseas
viral
infect
autoimmun
diseas
atherosclerosi
coronari
heart
diseas
cancer
neurolog
disord
increas
bal
describ
adult
granulomat
lung
diseas
sarcoidosi
tuberculosi
hypersensit
pneumon
radiat
pneumon
children
expos
secondhand
smoke
importantli
level
increas
pediatr
ard
highfrequ
oscillatori
ventil
ali
patient
wellrecogn
ali
candid
gene
ali
biomark
produc
wide
rang
cell
includ
ec
respons
stimul
endotoxin
tnfa
acutephas
respons
stimul
synthesi
creactiv
protein
hepatocyt
vitro
vivo
elev
level
describ
acut
condit
burn
major
surgeri
sepsi
may
predict
develop
multipl
organ
failur
sever
ard
differ
orgin
sepsi
acut
pancreat
elev
level
persist
circul
associ
increas
mortal
critic
ill
patient
ard
sepsi
trauma
concentr
shown
elev
bal
fluid
patient
establish
sever
ali
function
polymorph
promot
region
gene
exist
c
allel
associ
reduc
gene
promot
activ
lower
circul
concentr
lower
mortal
rate
patient
acut
respiratori
failur
admit
icu
multispeci
ali
studi
perform
signific
gene
express
across
speci
well
differenti
regionspecif
express
canin
ali
model
note
fact
suggest
role
ali
complex
may
dual
role
tempor
respons
sepsi
mechan
stress
pbef
gene
one
hand
gene
extrem
high
level
express
across
rang
ali
model
use
human
ali
sampl
wherea
first
report
pbef
significantli
upregul
lung
well
model
lung
injuri
publish
literatur
pbef
quit
spars
gene
encod
proinflammatori
cytokin
origin
describ
role
matur
bcell
precursor
gene
express
upregul
amniot
membran
patient
undergo
prematur
labor
especi
amniot
infect
pbef
protein
level
significantli
increas
bal
fluid
serum
human
murin
canin
ali
model
well
cytokineor
csactiv
lung
microvascular
endothelium
tripl
immunohistochem
stain
canin
lung
reveal
coloc
increas
pbef
express
lung
endothelium
type
ii
alveolar
epitheli
cell
infiltr
neutrophil
well
upregul
pbef
express
inflammatori
cytokinestimul
human
pulmonari
microvascular
ec
vitro
result
support
pbef
potenti
biomark
ali
potenti
involv
inflammatori
lung
process
notion
support
recent
studi
patient
sepsi
convincingli
demonstr
pbef
inhibit
neutrophil
apoptosi
common
variant
human
pbef
gene
also
confirm
associ
suscept
sepsisassoci
ali
allel
singlenucleotid
polymorph
pbef
promot
region
associ
nearli
twofold
decreas
report
gene
express
result
consist
observ
anim
model
ali
human
patient
ali
vitro
cell
cultur
experi
suggest
higher
express
pbef
implic
pathogenesi
ali
result
suggest
genet
determin
increas
pbef
express
contribut
suscept
ali
despit
decad
frustrat
pursuit
potent
barrierregulatori
therapi
progress
made
allevi
human
suffer
associ
uncontrol
lung
vascular
leakag
alveolar
flood
novel
biolog
compat
agent
identifi
preserv
restor
vascular
integr
leverag
new
insight
mechan
govern
integr
vascular
endothelium
particularli
role
cytoskelet
linkag
junction
protein
addit
sever
endotheli
target
protein
protein
pathway
particip
also
serv
potenti
novel
biomark
manag
patient
newli
revis
scientif
armamentarium
offer
promis
futur
manag
pulmonari
edema
associ
increas
vascular
leak
critic
ill
well
lung
condit
exhibit
strongli
dysregul
barrier
function
radiat
pneumon
acut
chest
syndrom
sickl
cell
patient
subacut
inflammatori
disord
asthma
nearli
barrierregulatori
agent
discuss
herein
success
evalu
preclin
model
ali
one
agent
phase
iii
trial
wherea
three
agent
statin
apc
mntx
current
approv
food
drug
administr
medic
condit
thu
prospect
rapid
translat
lung
vascular
barrierprotect
strategi
clinic
practic
high
addit
translat
benchtobedsid
genom
genet
strategi
approach
combin
dissect
basic
mechan
endotheli
structurefunct
inflamm
lead
greater
specif
advanc
clinic
trial
agent
treatment
inflammatori
lung
injuri
manner
repres
person
medicin
critic
ill
individu
